Compare ENVA & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENVA | TVTX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.3B |
| IPO Year | 2011 | 2013 |
| Metric | ENVA | TVTX |
|---|---|---|
| Price | $175.60 | $52.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $238.50 | $75.21 |
| AVG Volume (30 Days) | 285.2K | ★ 1.5M |
| Earning Date | 10-22-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.05 | ★ 92.89 |
| EPS | ★ 7.45 | N/A |
| Revenue | ★ $3,151,653,000.00 | N/A |
| Revenue This Year | $158.78 | $47.65 |
| Revenue Next Year | $17.63 | $49.39 |
| P/E Ratio | $24.17 | ★ N/A |
| Revenue Growth | ★ 18.58 | N/A |
| 52 Week Low | $115.06 | $22.59 |
| 52 Week High | $267.45 | $68.73 |
| Indicator | ENVA | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 38.26 |
| Support Level | $167.09 | $41.75 |
| Resistance Level | $176.20 | $59.93 |
| Average True Range (ATR) | 4.96 | 2.31 |
| MACD | 2.19 | 0.08 |
| Stochastic Oscillator | 44.47 | 31.09 |
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.